[HTML][HTML] 2-Oxoglutarate-dependent dioxygenases in cancer
JA Losman, P Koivunen, WG Kaelin Jr - Nature Reviews Cancer, 2020 - nature.com
Oxoglutarate-dependent dioxygenases (2OGDDs) are a superfamily of enzymes that play
diverse roles in many biological processes, including regulation of hypoxia-inducible factor …
diverse roles in many biological processes, including regulation of hypoxia-inducible factor …
The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes
DA Sallman, A List - Blood, The Journal of the American Society …, 2019 - ashpublications.org
In cancer biology, tumor-promoting inflammation and an inflammatory microenvironment
play a vital role in disease pathogenesis. In the past decade, aberrant innate immune …
play a vital role in disease pathogenesis. In the past decade, aberrant innate immune …
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
H Yang, C Bueso-Ramos, C DiNardo, MR Estecio… - Leukemia, 2014 - nature.com
Blockade of immune checkpoints is emerging as a new form of anticancer therapy. We
studied the expression of programmed death ligand 1 (PD-L1), PD-L2, programmed death 1 …
studied the expression of programmed death ligand 1 (PD-L1), PD-L2, programmed death 1 …
Chronic immune response dysregulation in MDS pathogenesis
L Barreyro, TM Chlon… - Blood, The Journal of …, 2018 - ashpublications.org
Chronic innate immune signaling in hematopoietic cells is widely described in
myelodysplastic syndromes (MDS), and innate immune pathway activation, predominantly …
myelodysplastic syndromes (MDS), and innate immune pathway activation, predominantly …
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism
Recent studies on mutations in cancer genomes have distinguished driver mutations from
passenger mutations, which occur as byproducts of cancer development. The cancer …
passenger mutations, which occur as byproducts of cancer development. The cancer …
Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia
X Yang, L Ma, X Zhang, L Huang, J Wei - Experimental Hematology & …, 2022 - Springer
Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are clonal
hematopoietic stem cell diseases arising from the bone marrow (BM), and approximately …
hematopoietic stem cell diseases arising from the bone marrow (BM), and approximately …
[HTML][HTML] Adaptive response to inflammation contributes to sustained myelopoiesis and confers a competitive advantage in myelodysplastic syndrome HSCs
T Muto, CS Walker, K Choi, K Hueneman… - Nature …, 2020 - nature.com
Despite evidence of chronic inflammation in myelodysplastic syndrome (MDS) and cell-
intrinsic dysregulation of Toll-like receptor (TLR) signaling in MDS hematopoietic stem and …
intrinsic dysregulation of Toll-like receptor (TLR) signaling in MDS hematopoietic stem and …
[HTML][HTML] Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9
Impaired erythropoiesis in the deletion 5q (del (5q)) subtype of myelodysplastic syndrome
(MDS) has been linked to heterozygous deletion of RPS14, which encodes the ribosomal …
(MDS) has been linked to heterozygous deletion of RPS14, which encodes the ribosomal …
[HTML][HTML] Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes
N Daver, P Boddu, G Garcia-Manero, SS Yadav… - Leukemia, 2018 - nature.com
Immune checkpoint inhibitors, as single-agent therapy, have shown modest clinical efficacy
in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). As …
in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). As …
Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes
I Gañán-Gómez, Y Wei, DT Starczynowski, S Colla… - Leukemia, 2015 - nature.com
Myelodysplastic syndromes (MDSs) are a group of heterogeneous clonal hematologic
malignancies that are characterized by defective bone marrow (BM) hematopoiesis and by …
malignancies that are characterized by defective bone marrow (BM) hematopoiesis and by …